Graph and download economic data for 18-Year High Quality Market (HQM) Corporate Bond Spot Rate (HQMCB18YR) from Jan 1984 to Jun 2025 about bonds, corporate, interest rate, interest, rate, and USA.

Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti-inflammatory data was reported at 0.048 % in 2018. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti-inflammatory data is updated yearly, averaging 0.048 % from Dec 2018 (Median) to 2018, with 1 observations. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti-inflammatory data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I007: Consumer Price Index: Weights: Second Half July 2018=100.

Financial overview and grant giving statistics of Mmd Family Foundation

Mexico Consumer Price Index (CPI): HC: MMD: MD: Glasses, Orthopedically & Hearing Aids data was reported at 105.365 16Jul2018-31Jul2018=100 in Mar 2019. This records an increase from the previous number of 105.098 16Jul2018-31Jul2018=100 for Feb 2019. Mexico Consumer Price Index (CPI): HC: MMD: MD: Glasses, Orthopedically & Hearing Aids data is updated monthly, averaging 74.266 16Jul2018-31Jul2018=100 from Jul 2002 (Median) to Mar 2019, with 201 observations. The data reached an all-time high of 105.365 16Jul2018-31Jul2018=100 in Mar 2019 and a record low of 52.647 16Jul2018-31Jul2018=100 in Jul 2002. Mexico Consumer Price Index (CPI): HC: MMD: MD: Glasses, Orthopedically & Hearing Aids data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I002: Consumer Price Index: Second Half July 2018=100.

Financial overview and grant giving statistics of Mmd Foundation Inc.

599 Global export shipment records of Mn Ore Mmd with prices, volume & current Buyer's suppliers relationships based on actual Global export trade database.

Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti-allergic data was reported at 0.026 % in 2018. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti-allergic data is updated yearly, averaging 0.026 % from Dec 2018 (Median) to 2018, with 1 observations. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti-allergic data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I007: Consumer Price Index: Weights: Second Half July 2018=100.

2226 Global exporters importers export import shipment records of Mn ore mmd with prices, volume & current Buyer's suppliers relationships based on actual Global export trade database.

Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines data was reported at 0.661 % in 2017. This stayed constant from the previous number of 0.661 % for 2016. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines data is updated yearly, averaging 0.661 % from Dec 2010 (Median) to 2017, with 8 observations. The data reached an all-time high of 1.041 % in 2012 and a record low of 0.661 % in 2017. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I008: Consumer Price Index: Weights: Second Half December 2010=100.

Historical ownership data of MMD by AMERIPRISE FINANCIAL INC

The Myotonic Muscular Dystrophy (MMD) Treatments market is experiencing steady growth, projected to reach a market size of $2.5 Billion by 2025, with a Compound Annual Growth Rate (CAGR) of 5%. This growth is driven by several factors. Increasing prevalence of MMD, coupled with advancements in understanding the disease's underlying mechanisms, are fueling the development of novel therapies. The pipeline includes promising gene therapies and targeted medications aimed at addressing the core pathology of MMD, offering hope for improved patient outcomes. The market is segmented by treatment type (medications, rehabilitative therapies, devices, surgeries) and application (hospitals, specialty clinics, ambulatory surgery centers). While medications currently dominate the market share, the increasing adoption of innovative rehabilitative therapies and advanced devices is anticipated to drive substantial growth in these segments over the forecast period (2025-2033). North America and Europe currently hold the largest market share due to higher healthcare expenditure and robust research and development activities in these regions. However, emerging economies in Asia-Pacific are poised for significant expansion, driven by rising awareness and increasing healthcare infrastructure development. Regulatory approvals for new therapies and increasing patient advocacy are also key drivers for market expansion. Despite positive growth projections, the market faces certain restraints. High treatment costs associated with novel therapies, along with the complexity and length of clinical trials for new drug development, pose significant challenges. Furthermore, the relatively low prevalence of MMD compared to other neuromuscular diseases limits the overall market size. However, ongoing research efforts and collaborative initiatives between pharmaceutical companies, research institutions, and patient advocacy groups are working to overcome these barriers and accelerate the development of effective and affordable MMD treatments. The long-term outlook for the MMD treatment market remains optimistic, with continued advancements likely to significantly improve the quality of life for patients affected by this debilitating disease.

Ferroptosis is a form of regulated cell death with roles in degenerative diseases and cancer. Excessive iron-catalyzed peroxidation of membrane phospholipids, especially those containing the polyunsaturated fatty acid arachidonic acid (AA), is central in driving ferroptosis. Here, we reveal that an understudied Golgi-resident scaffold protein, MMD, promotes susceptibility to ferroptosis in ovarian and renal carcinoma cells in an ACSL4- and MBOAT7-dependent manner. Mechanistically, MMD physically interacts with both ACSL4 and MBOAT7, two enzymes that catalyze sequential steps to incorporate AA in phosphatidylinositol (PI) lipids. Thus, MMD increases the flux of AA into PI, resulting in heightened cellular levels of AA-PI and other AA-containing phospholipid species. This molecular mechanism points to a pro-ferroptotic role for MBOAT7 and AA-PI, with potential therapeutic implications, and reveals that MMD is an important regulator of cellular lipid metabolism.

Historical ownership data of MMD by UBS Group AG

2632 Global exporters importers export import shipment records of Mmd manganese with prices, volume & current Buyer's suppliers relationships based on actual Global export trade database.

Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti inflammatory data was reported at 0.015 % in 2017. This stayed constant from the previous number of 0.015 % for 2016. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti inflammatory data is updated yearly, averaging 0.015 % from Dec 2010 (Median) to 2017, with 8 observations. The data reached an all-time high of 0.040 % in 2012 and a record low of 0.015 % in 2017. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Anti inflammatory data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I008: Consumer Price Index: Weights: Second Half December 2010=100.

Number of CALHIV with a VL test result within the past 12 months at 36 SIDHAS-supported sites, by age group and quarter (October 2019–March 2021).

Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Dermatological data was reported at 0.011 % in 2017. This stayed constant from the previous number of 0.011 % for 2016. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Dermatological data is updated yearly, averaging 0.011 % from Dec 2010 (Median) to 2017, with 8 observations. The data reached an all-time high of 0.012 % in 2012 and a record low of 0.011 % in 2017. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Dermatological data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I008: Consumer Price Index: Weights: Second Half December 2010=100.

[This protein is expressed by in vitro differentiated macrophages but not freshly isolated monocytes. Although sequence analysis identifies seven poten ]

Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Healing Materials data was reported at 0.028 % in 2017. This stayed constant from the previous number of 0.028 % for 2016. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Healing Materials data is updated yearly, averaging 0.028 % from Dec 2010 (Median) to 2017, with 8 observations. The data reached an all-time high of 0.045 % in 2012 and a record low of 0.028 % in 2017. Mexico Consumer Price Index (CPI): Weights: HC: MMD: Medicines: Healing Materials data remains active status in CEIC and is reported by National Institute of Statistics and Geography. The data is categorized under Global Database’s Mexico – Table MX.I008: Consumer Price Index: Weights: Second Half December 2010=100.

Months of stock by pediatric ARV medication at 36 SIDHAS-supported sites (October–December 2019 vs. January–March 2021).